Clinical Trial Update: Pazopanib and Paclitaxel for Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pazopanib in combination with paclitaxel for non-small cell lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Pazopanib (Pazopanib)

Snippet

Sponsor: Loyola University | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: WITHDRAWN